Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis [version 1; referees: 3 approved]

Tara L. Hogenson¹, Matthias Lauth², Marina Pasca diMagliano³, Martin E. Fernandez-Zapico¹

¹Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
²Institute of Molecular Biology and Tumor Research, Philipps University, Marburg, 35043, Germany
³Department of Surgery, University of Michigan, Ann Arbor, MI 48109-5936, USA

Abstract
Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.
Introduction

The protein GLI1, originally isolated in 1987 due to high levels of amplification in malignant glioma (Kinzler et al., 1987), is a member of the GLI family of transcription factors. This family also includes GLI2 and GLI3. GLI1 is highly conserved from Drosophila to humans and is required for developmental response via transcriptional regulation of target genes (Dennler et al., 2007; Hui & Angers, 2011; Javelaud et al., 2012). The GLI proteins, including GLI1, are transcriptional mediators of Hedgehog (HH) signaling, and regulate multiple cellular processes such as cell fate determination, tissue patterning, proliferation and transformation, which give this transcription factor a significant role in carcinogenesis if deregulated (Dennler et al., 2007; Hui & Angers, 2011; Javelaud et al., 2012). GLI1 is expressed in different human malignancies including pancreatic ductal adenocarcinoma (PDAC) (Eberl et al., 2012; Fiaschi et al., 2009; Goel et al., 2013; Hui & Angers, 2011; Mills et al., 2013; Rajurkar et al., 2012; Thayer et al., 2003). In PDAC, GLI1 is prevalently expressed in the stroma, in response to HH ligands secreted by the epithelial cells (Yauch et al., 2008).

GLI1 as an oncogene in PDAC

GLI1 plays a key role in PDAC initiation by modulating the activity of two different cellular compartments, the epithelium and stroma. Rajurkar et al. demonstrated that targeted overexpression of GLI1 in the pancreas epithelium accelerates PDAC initiation by KRAS, a small GTPase mutated in more than 90% of PDAC cases (Rajurkar et al., 2012). Through use of a mouse model with simultaneous activation of oncogenic KRAS and inhibition of GLI1 in the pancreas epithelium, this group also demonstrated that decreased GLI1 activity reduced the incidence of KRAS-driven PDAC precursor lesions (pancreatic intraepithelial neoplasias or PanINs) and PDAC. Similarly, Mills and colleagues using a mouse model for pancreas-specific oncogenic KRAS expression (KC mice) bred on a Gli1 null background (GKO/KC) defined a key role for GLI1 on PDAC initiation through the modulation of the activity of fibroblasts (Mills et al., 2013). The KC mice developed PanIN lesions with 100% penetrance and PDAC in advanced age, while the GKO/KC mice did not develop PDAC and had increased survival rate when compared to KC mice. Histopathological analysis of the pancreata showed KC mice developed PanIN lesions and PDAC, while 80% of GKO/KC had normal pancreata.

Analysis of the molecular mechanism underlying this phenomenon reveals that GLI1 both regulates different target genes and is modulated by different signaling pathways depending on the cellular compartment. For instance, GLI1 activity is mainly modulated by the canonical HH signaling in fibroblasts (Yauch et al., 2008). This cascade is activated by binding of the ligand to the receptor Patched (Ptc), resulting in activation of the G-coupled receptor, Smoothened (Smo) (Javelaud et al., 2012; Yauch et al., 2008). Once activated, Smo induces GLI1 activation and upregulation of its target genes (Hui & Angers, 2011; McMahon et al., 2003). The HH ligand, Sonic Hedgehog (SHH), and components of the HH signaling pathway, including Ptc and Smo, are undetectable in the normal pancreas but overexpressed in PanINs and PDAC (Thayer et al., 2003). Inhibition of the HH pathway in PDAC cell-based xenograft models through Smo inhibition has been shown to reduce GLI1 activity and tumor growth (Feldmann et al., 2007; Thayer et al., 2003; Yauch et al., 2008). In addition, genomic sequencing of human pancreatic cancer samples revealed widespread mutations consistent with activation of the Hedgehog signaling pathway (Jones et al., 2008). While the association between HH activity and pancreatic cancer has been described over a decade ago, there is still uncertainty as to the downstream effect of HH activation in this disease. Mills et al. identified the cytokine IL-6 as a HH/GLI1 target gene in pancreatic fibroblasts (Mills et al., 2013). Increased IL-6 expression in the stromal compartment induces activation of STAT3 in the neighboring cancer cells, an essential molecular event for the progression of premalignant lesions in PDAC (Figure 1).

Hedgehog-independent mechanisms for GLI1 expression in PDAC

While dysregulation of HH-GLI1 signaling has been shown to play an important role in PDAC formation, several studies have demonstrated that GLI1 expression can be activated through HH-independent mechanisms in PDAC, particularly in the epithelial compartment (Dennler et al., 2007; Eberl et al., 2012; Goel et al., 2013; Ji et al., 2007; Nolan-Stevaux et al., 2009; Nye et al., 2014). Nolan-Stevaux et al. demonstrated that deletion of Smo receptor in pancreatic epithelium had no effect on KRAS induced tumor formation, nor on GLI1 expression in epithelial cells (Nolan-Stevaux et al., 2009). This indicates a Smo-independent mechanism for GLI1 regulation in PDAC cells downstream of KRAS. In fact, Ji et al. demonstrated that KRAS is a modulator of GLI1 activity and requires the transcription factor for PDAC growth in vitro (Ji et al., 2007). In the epithelial compartment, GLI1 is regulated in a HH-independent manner, downstream of KRAS. Accordingly, Ji et al. showed that Gli1 protein degradation is blocked in a MAPK-dependent manner. Furthermore, Rajurkar et al. showed a role for GLI1 in the regulation of the NF-kB pathway, a signaling cascade linked to PDAC development (Aigul et al., 2002; Ougolkov et al., 2005; Pan et al., 2008; Wang et al., 1999), downstream of KRAS (Rajurkar et al., 2012). This group has identified the I-kappa-B kinase epsilon (IkBKE/NF-kB) pathway as a direct target of the GLI1 mediating KRAS-dependent pancreatic epithelial transformation in vivo (Junhao Mao, University of Massachusetts and Martin E. Fernandez-Zapico personal communication).

PDAC is characterized by a dense desmoplastic reaction associated with the primary tumor. The abundance of connective tissue is due to an increase in growth factor production in the tumor microenvironment through autocrine and paracrine oncogenic signaling pathways (Mahadevan & Von Hoff, 2007). Oncogenic KRAS activates SHH production, but HH ligands do not activate the HH pathway in tumor epithelial cells in an autocrine manner (Lauth et al., 2010; Mills et al., 2013; Yauch et al., 2008). HH signaling in PDAC occurs in a paracrine fashion where HH signaling from PDAC cells to stromal cells has been shown to promote desmoplasia (Yauch et al., 2008). Lauth et al. demonstrated that this shift from autocrine to paracrine signaling is through activation of the RAS effector dual specificity tyrosine phosphorylated and regulated kinase 1B (DYRK1B) (Lauth et al., 2010). The authors proposed this is achieved through DYRK1B inhibition of GLI2 function and promotion of the repressor GLI3, and subsequent inhibition of GLI1, in PDAC cells.
TGFβ has been shown to promote GLI1 expression in pancreatic cancer cells (Nolan-Stevaux et al., 2009). TGFβ induces the expression of GLI1 through Smad3 and LET-dependent upregulation of GLI2 independent of HH signaling (Dennler et al., 2007; Dennler et al., 2009). Nye et al. demonstrated that TGFβ, in addition to controlling GLI1 expression, can also modulate its activity by promoting the formation of a transcriptional complex with the TGFβ-regulated transcription factors, SMAD2 and 4, and the histone acetyltransferase, PCAF, in cancer cells to regulate TGFβ-induced gene expression (Nye et al., 2014). TGFβ-induced GLI2 expression, and subsequent GLI1 activation, is associated with epithelial to mesenchymal transition (EMT), tumor growth, and metastasis (Javelaud et al., 2012).

In addition to TGFβ and KRAS activation, epidermal growth factor receptor (EGFR) signaling, a cascade aberrantly activated in the majority of PDACs, has been demonstrated to play a critical role in HH/GLI1-regulated tumor-initiating pancreatic cancer cells (Eberl et al., 2012). Eberl and colleagues demonstrated EGFR and HH act together to promote cancer cell proliferation by modulating gene expression through a GLI1-dependent mechanism. This suggests HH/GLI1 signaling works synergistically through distinct novel pathways during tumor initiation and growth.

Clinical trials targeting the hedgehog/GLI1 axis in PDAC
The concept that HH/GLI1 signaling might be required for PDAC growth, hence a suitable therapeutic target, has been first validated in a genetically engineered mouse model of pancreatic cancer that combines expression of oncogenic Kras with mutation of the tumor suppressor p53, the KPC mouse (Hingorani et al., 2005). Treatment of KPC mice with a Smo inhibitor in combination with gemcitabine led to a moderate but significant increase in survival (Feldmann et al., 2008; Olive et al., 2009). A preclinical study of the HH inhibitor, saridegib (IPI-926), co-administered with gemcitabine, produced a transient increase in vascular density, increased chemotherapy drug delivery, and improved disease stabilization in pancreatic cancer cells (Olive et al., 2009). Based on these results, phase II clinical trials were approved evaluating saridegib and an additional Hh inhibitor, vismodegib (GDC-0449), for treatment of pancreatic cancer. Surprisingly, the clinical trial for both vismodegib and saridegib showed a higher rate of progressive disease when compared to placebo (Catenacci et al., 2013). Similar findings were seen in a separate phase I trial of vismodegib in 8 patients with pancreatic cancer (LoRusso et al., 2011). Although hedgehog inhibitors have been successful for treating basal cell carcinoma and medulloblastoma, they do not appear to have the same effect in advanced pancreatic cancer.
These disappointing results left investigators questioning the molecular mechanism responsible for these failed clinical trials. Although there is overwhelming evidence that GLI1 plays an important role in tumor initiation and progression of several kinds of malignancies, these results suggest the transcription factor may have a tumor protective role in the later stages of certain cancers. In fact, recent studies investigating GLI1 expression in PDAC have revealed GLI1 may switch from a tumor promoting to a tumor protective molecule in the later stages of PDAC.

**GLI1 as a tumor suppressor in PDAC**

In contrast to the current paradigm for GLI1 expression and tumor progression, one study found GLI1 expression may actually decrease cell motility in advanced PDAC (Joost et al., 2012). Joost et al. demonstrated that GLI1 regulates epithelial differentiation through transcriptional activation of the cell adhesion molecule, E-Cadherin (CDH1), in PDAC cells. Lowered expression of GLI1 in PDAC cells lead to a loss of CDH1 expression and promotion of EMT. The transition from epithelial to motile mesenchymal cells is thought to be a critical event for metastasis of carcinomas. Decreased expression of CDH1 is associated with increased metastasis and invasion, while increased expression is associated with lower tumor malignancy (Seidel et al., 2004; von Burstin et al., 2009). PDAC is strongly associated with early invasion and metastasis. Loss of GLI1 was also shown to decrease expression of additional important epithelial marker genes, including Keratin 19 (KRT19) and adherens junctions components EVA1 and PTPRM, leading to increased cell motility. This indicates that as PDAC progresses, lower GLI1 levels may actually prime tumor cells towards an EMT program, which would be associated with metastasis and advanced stages of the disease.

Mills et al. examined the role of GLI1 expression in the later stages of PDAC using a mouse model for advanced pancreatic cancer (Mills et al., 2014). In this study, the loss of GLI1 actually accelerated PDAC progression during the later stages of tumorigenesis. PDAC mice lacking GLI1 showed reduced survival when compared to GLI1 wild type littermates. While both cohorts of mice displayed the common features of advanced PDAC, loss of GLI1 was associated with decreased survival and increased tumor burden. Analysis of the mechanism revealed the pro-apoptotic FAS/FASL axis as a potential mediator for this phenomenon. Loss of GLI1 was associated with a significant decrease in expression of FAS/FASL, leading to lower apoptosis levels and increased tumor progression (Figure 1).

In agreement with these findings, two recent studies demonstrated that the deletion of the GLI1 inducer SHH, using a mouse model for PDAC, led to more aggressive tumors (Lee et al., 2014; Rhim et al., 2014). Interestingly, Rhim’s study reported the occurrence of poorly differentiated tumors, with increased vascularity, and significantly reduced stromal content. In contrast, the Lee paper only described a modest reduction in the stromal compartment. The current paradigm for PDAC is that the tumor stroma plays an important role in promotion of neoplastic growth and progression since PDAC is typically associated with a dense desmoplastic reaction. However, the Rhim study shows that tumors with reduced stroma may display a more aggressive behavior than those with an extensive stromal compartment. This concept is further supported by a recent report demonstrating that tumor stroma restrains pancreatic cancer progression and that pharmacological HH pathway activation in stromal cells can actually slow down in vivo tumorigenesis (Lee et al., 2014). The complexity of these findings reflects our incomplete understanding of the precise biological role of HH/GLI1 signaling in pancreatic cancer. In fact, the level of activation of HH signaling might induce different biological responses during the carcinogenesis process, as commonly observed during embryonic development. In fact, manipulation of the membrane mediators of HH signaling to reduce HH signaling leads to an increase of angiogenesis with low HH levels, but not with complete inhibition. Intriguingly, the Rhim and Lee studies generated a low HH signaling environment by eliminating SHH, but not IHH, another HH ligand expressed in pancreatic cancer. Similarly, studies altering the expression of Gl1 leave intact the other mediators of HH signaling, GLI2 and GLI3 (the latter mainly an inhibitor of HH target genes). It remains to be seen if manipulating GLI1 levels within the epithelial tumor compartment in later stages of disease is of any therapeutic value. Based on work from Fendrich et al. on HH signaling and acinar cell differentiation, it might even be provocatively proclaimed that increasing GLI1 levels could drive terminal differentiation and thus result in lower tumorigenicity (Fendrich et al., 2008).

**Discussion**

These studies demonstrating GLI1 may act as a tumor suppressor in the late stage of PDAC give insight into the disappointing results of clinical trials testing HH inhibitors in metastatic PDAC patients. While the Olive experiments reported acute administration of IPI-926 increased survival due to decreased stromal content and increased vascularity, the HH inhibitor performed poorly in pancreatic cancer clinical trials in patients. One explanation for this discrepancy may be the short duration of treatment (3 weeks) in the Olive’s experiments, which may have not accurately detected disease progression following HH inhibition. This indicates that as PDAC progresses, the initial positive effects of HH inhibition may be eliminated as GLI1 levels decrease. In Rhim’s study, the authors discovered that SHH and GLI1 deficient tumors were more aggressive, poorly differentiated, and exhibited increased vascularity (Rhim et al., 2014). This suggests HH/GLI1 pathway inhibition may have a proangiogenic effect. Due to the increase in vascularity of the SHH deficient mice tumors, the authors investigated the effect of angiogenesis inhibition by administering anti-VEGF to tumor-bearing SHH deficient mice. This therapy led to a significant improvement in the overall survival of mice with undifferentiated tumors. Based on this response, the subset of PDAC patients with undifferentiated tumors may benefit from anti-angiogenic therapy. In summary, due to the high complexity of PDAC initiation and progression, a personalized strategy for treatment should be considered. Under this strategy, PDAC should be analyzed before treatment to determine expression of GLI1 and upstream regulators in order to better define therapeutic options.

**Author contributions**

T.L.H and M.E.F.-Z. developed the concept of the review and T.L.H, M.L., M.P.M. and M.E.F.-Z. wrote the manuscript.
Competing interests
No competing interests were disclosed.

Grant information
This work was supported by National Institutes of Health Grant CA136526, Division of Oncology Research (Mayo Clinic), Mayo Clinic Pancreatic SPORE P50 Grant CA102701 and Mayo Clinic Center for Cell Signaling in Gastroenterology Grant P30 DK84567 (to M.E.F.-Z.).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments
We thank Emily Porcher and Pam Becker for secretarial assistance.

References

Barbara Stecca
Laboratory of Tumor Cell Biology, Core Research Laboratory-Istituto Toscano Tumori, Florence, Italy

This review provides a comprehensive summary about the role of the transcription factor GLI1 in pancreatic cancer (PDAC). This manuscript highlights the dual role of GLI1 during pancreatic carcinogenesis, acting as an oncogene in the early stages of disease and as a tumor-suppressor in the late stages. Recent evidence suggests the loss of GLI1 in the later stages of PDAC might accelerate disease progression. This might explain why Smoothened (SMO) inhibitors have been successful for treating basal cell carcinoma and medulloblastoma, but do not appear to have the same effect in metastatic PDAC. Moreover, this article summarizes recent data on the integration of GLI1 with other signaling pathways, suggesting that GLI1 is not only regulated by the upstream Hedgehog signaling in a SMO-dependent manner, but also by other oncogenic inputs, such as KRAS, TGF-beta and EGFR signaling.

Recent experimental data suggest that lower GLI1 levels associate with PDAC progression, whereas increasing GLI1 levels could drive terminal differentiation and decreased PDAC tumorigenicity. What is missing in this review is a consideration about the factors that might contribute to decrease GLI1 levels and activity during PDAC progression. I would also suggest to mention in the Discussion that the dual role of GLI1 is so far limited to PDAC, as the evidence is lacking in other cancer types.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Author Response (Member of the F1000 Faculty) 14 Jun 2016

Martin Fernandez-Zapico, Schulze Center for Novel Therapeutics, Mayo Clinic in Rochester, USA

1. Recent experimental data suggest that lower GLI1 levels associate with PDAC progression, whereas increasing GLI1 levels could drive terminal differentiation and decreased PDAC tumorigenicity. What is missing in this review is a consideration about the factors that might contribute to decrease GLI1 levels and activity during PDAC progression.
**Response:** We added additional considerations regarding other factors that may drive down GLI1 levels during PDAC progression to the “Discussion” section. Mechanisms included are activation of DYRK1B kinase, which promotes a shift from autocrine to paracrine signaling, which may lead to decreased GLI1 expression. Also, decreased HH signaling in advanced PDAC may allow for increased expression of GLI1 repressors.

2. **I would also suggest to mention in the Discussion that the dual role of GLI1 is so far limited to PDAC, as the evidence is lacking in other cancer types.**

**Response:** The following statement was added to the final paragraph of the Discussion section “Further studies are needed to fully understand the role of GLI1 in PDAC carcinogenesis. While there is evidence for a dual role of GLI1 in PDAC, this phenomenon has yet to be linked with other cancer types.”

**Competing Interests:** None

---

**Natalia Riobo**
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

The review is timely and addresses a very important problem in pancreatic cancer. The Smoothened inhibitors that work well for other tumor types have not only failed to stop the progression, but instead promote aggressive behavior in pancreatic cancer. The authors make a good case of balancing the evidence that suggests that there is HH-independent upregulation of GLI1 in the epithelial cells and a Hh-dependent upregulation in fibroblasts. Moreover, they nicely discuss how GLI1 is necessary for PanIN formation and then restrains further cancer progression. What is lacking in the review is a consideration of potential non-canonical effects of the Smo inhibitors. It is known that Smo induces cytoskeletal changes in fibroblasts, for instance, and that it can regulate glucose uptake in other cell types. Perhaps modulation of GLI1 is a bystander effect confusing the results. And the GLI1 knockout animals only partly acknowledge this interpretation, since some effects can be cell-type specific and opposing, as discussed in the review.

A minor criticism is the following: the introduction erroneously says that GLI1 is conserved from Drosophila to humans. However, GLI3 is the closest homolog in sequence and function to Drosophila Ci. It seems that the authors meant the GLI family is conserved.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

**Competing Interests:** No competing interests were disclosed.
1. What is lacking in the review is a consideration of potential non-canonical effects of the Smo inhibitors. It is known that Smo induces cytoskeletal changes in fibroblasts, for instance, and that it can regulate glucose uptake in other cell types. Perhaps modulation of GLI1 is a bystander effect confusing the results. And the GLI1 knockout animals only partly acknowledge this interpretation, since some effects can be cell-type specific and opposing, as discussed in the review.

Response: Additional considerations were added concerning the use of SMO inhibitors and downstream GLI-independent effects to the Discussion section.

2. A minor criticism is the following: the introduction erroneously says that GLI1 is conserved from Drosophila to humans. However, GLI3 is the closest homolog in sequence and function to Drosophila Ci. It seems that the authors meant the GLI family is conserved.

Response: This statement was corrected to “the GLI family of transcription factors is highly conserved and is required for developmental response via transcriptional regulation of target genes” in the Introduction. The statement regarding Drosophila to humans was removed.

Competing Interests: None

Referee Report 16 October 2014
doi:10.5256/f1000research.5682.r6370

Alain Mauviel
Team “TGF-β and Oncogenesis”, Centre de Recherche, Institut Curie, Orsay, France

In this article Hogenson et al. provide us with a timely review regarding the current knowledge about the role of the transcription factor GLI1 in pancreatic carcinoma. There is an important focus on the dual activity of GLI1 during pancreatic carcinogenesis depending on the stage of disease progression, as evidenced in most recent works in this field, both clinical and experimental, that are nicely summarized in this review. Another important aspect of this review consists in integrating GLI1 as a transcription factor that is not solely regulated by Hedgehog signaling downstream of SMO but also by other pro-tumorigenic pathways, such as TGF-beta and KRAS signaling.

Overall, I believe that this manuscript is very focused and contains valuable information for the broader readership, with up-to-date citation of the most relevant and recent literature in the field.

A couple of minor points may be corrected or improved:
1. A figure summarizing the role of GLI1 downstream of the various pathways described to modulate its expression/activity would be helpful.

2. On page 3, one reads “TGFβ induces the expression of GLI1 through Smad3 and LET-dependent up regulation of GLI2”. "LET-dependent" should be replaced by beta-catenin/LEF-TCF-dependent or something similar.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

---

**Author Response (Member of the F1000 Faculty) 14 Jun 2016**

**Martin Fernandez-Zapico**, Schulze Center for Novel Therapeutics, Mayo Clinic in Rochester, USA

1. A figure summarizing the role of GLI1 downstream of the various pathways described to modulate its expression/activity would be helpful.

   **Response:** An additional figure was added to the review (Figure 1) to describe the various pathways that modulate GLI1 expression as discussed in the review. Figure 1 from the first version of this article was changed to Figure 2.

2. On page 3, one reads “TGFβ induces the expression of GLI1 through Smad3 and LET-dependent up regulation of GLI2”. “LET-dependent” should be replaced by beta-catenin/LEF-TCF-dependent or something similar.

   **Response:** “LET-dependent” was corrected to “β-catenin/LEF-TCF-dependent” on page 3.

**Competing Interests:** None